Nadroparin calcium

Nadroparin calcium
Clinical data
Trade names	Fraxiparine, Fraxodi
AHFS/Drugs.com	International Drug Names
Routes of administration	SC (except for haemodialysis)
ATC code	B01AB06 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only
Pharmacokinetic data
Bioavailability	89% (SC dose)
Biological half-life	3.7 hours (SC dose)
Excretion	clearance 21.4mL/min (+/- 7)
Identifiers
IUPAC name (4S,6R)-6-[(2R,4R)-4,6-dihydroxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3,4-dihydroxy-5-sulfonatooxyoxane-2-carboxylate
CAS Number	9005-49-6^N
DrugBank	DB08813^N
ChemSpider	none
UNII	1K5KDI46KZ
KEGG	D07510^N
Chemical and physical data
Molar mass	4300 g/mol
^NY (what is this?) (verify)

Nadroparin (trade name, Fraxiparine or Fraxodi) is an anticoagulant belonging to a class of drugs called low molecular weight heparins (LMWHs). Nadroparin was developed by sanofi-synthelabo.

Nadroparin is used in general and orthopedic surgery to prevent thromboembolic disorders (deep vein thrombosis and pulmonary embolism), and as treatment for deep vein thrombosis. It is also used to prevent clotting during hemodialysis, and for treatment of unstable angina and non-Q wave myocardial infarction.^[1]

For the treatment and prevention of DVT, the drug is administered as a subcutaneous injection (under the skin), usually around the stomach. Injections are given once or twice daily depending on the condition.^[1]

References

1 2 Fraxiparine PRODUCT MONOGRAPH (Canada); http://www.aspripharma.com/pdf/Fraxiparine%20&%20Fraxi%20Forte%20PM_EN.pdf

External links

http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=483128
http://www.mayoclinic.com/health/drug-information/DR600971
Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A (2006). "A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study". Pharmacology. 78 (3): 136–43. PMID 17057417. doi:10.1159/000096484.

Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)

Antiplatelet drugs

Glycoprotein IIb/IIIa inhibitors	Abciximab Eptifibatide Orbofiban Roxifiban Sibrafiban^§ Tirofiban
ADP receptor/P2Y₁₂ inhibitors	Thienopyridines Clopidogrel Prasugrel Ticlopidine Nucleotide/nucleoside analogs Cangrelor Elinogrel Ticagrelor
Prostaglandin analogue (PGI2)	Beraprost Iloprost Prostacyclin Treprostinil
COX inhibitors	Acetylsalicylic acid/Aspirin^# Aloxiprin Carbasalate calcium Indobufen Triflusal
Thromboxane inhibitors	Thromboxane synthase inhibitors Dipyridamole (+ aspirin) Picotamide Terbogrel Receptor antagonists Terbogrel Terutroban^§
Phosphodiesterase inhibitors	Cilostazol Dipyridamole Triflusal
Other	Cloricromen Ditazole Vorapaxar

Anticoagulants

Vitamin K antagonists
(inhibit II, VII, IX, X)

Factor Xa inhibitors
(with some II inhibition)

Heparin group/ glycosaminoglycans/ (bind antithrombin)	Low molecular weight heparin Bemiparin Certoparin Dalteparin Enoxaparin Nadroparin Parnaparin Reviparin Tinzaparin^‡ Oligosaccharides Fondaparinux Idraparinux^§ Heparinoids Danaparoid Dermatan sulfate Sulodexide
Direct Xa inhibitors ("xabans")	Apixaban Betrixaban Darexaban^§ Edoxaban Otamixaban^§ Rivaroxaban

Direct thrombin (IIa) inhibitors

Other

Thrombolytic drugs/
fibrinolytics

Non-medicinal

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.